Clinical Trial Update: Olinvacimab With Pembrolizumab in Patients With mTNBC [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Olinvacimab in combination with pembrolizumab for metastatic triple-negative breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Olinvacimab (olinvacimab)

Snippet

Sponsor: PharmAbcine | Conditions: Metastatic Triple-Negative Breast Cancer | Phase 2 | Status: TERMINATED